Pazopanib: a promising new agent in the treatment of soft tissue sarcomas

被引：3

作者：

Kasper, Bernd ^{[1
]}

Hohenberger, Peter ^{[1
]}

机构：

[1] Heidelberg Univ, Mannheim Univ Med Ctr, Interdisciplinary Tumor Ctr Mannheim, Sarcoma Unit, D-68167 Mannheim, Germany

来源：

FUTURE ONCOLOGY | 2011年 / 7卷 / 12期

关键词：

angiogenesis inhibitor; pazopanib; renal cell carcinoma; soft tissue sarcoma; tyrosine kinase inhibitor; MULTIKINASE ANGIOGENESIS INHIBITOR; ENDOTHELIAL GROWTH-FACTOR; PHASE-II; EUROPEAN ORGANIZATION; EORTC; CHEMOTHERAPY; PROGRESSION; STRATEGIES; ET-743;

D O I：

10.2217/FON.11.116

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Pazopanib (GW786034) is a novel, small-molecule tyrosine kinase inhibitor. The primary mechanism of action of pazopanib can be described through its antiangiogenic properties via inhibition of the intracellular tyrosine kinase of VEGF receptor (VEGFR) and PDGF receptor (PDGFR). It is an orally available angiogenesis inhibitor that targets VEGFR-1, -2 and -3, PDGFR-alpha and -beta, and c-kit. Pazopanib exhibits distinct pharmacokinetic and toxicity profiles compared with other agents in that class. Phase I studies defined the recommended monotherapy dose of pazopanib as 800 mg once daily. In 2009, it was approved in the USA for the treatment of advanced and metastatic renal cell carcinoma, and subsequently approved in other countries and demonstrated clinically and statistically significant activity in Phase II and III studies in advanced soft tissue sarcoma patients. This article focuses on its emerging role in the treatment of advanced soft tissue sarcomas.

引用

页码：1373 / 1383

页数：11

共 37 条

[1]

*BAY HEALTHCARE PH, 2009, NEX SOR TABL PRESCR

[2]

Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma [J].

Bukowski, Ronald M. .

EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (05) :635-645

[3]

CHAWLA P, 2011, 2011 ASCO ANN M CHIC

[4]

Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[5]

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: Multicenter phase II and pharmacokinetic study [J].

Garcia-Carbonero, R ;

Supko, JG ;

Maki, RG ;

Manola, J ;

Ryan, DP ;

Harmon, D ;

Puchalski, TA ;

Goss, G ;

Seiden, MV ;

Waxman, A ;

Quigley, MT ;

Lopez, T ;

Sancho, MA ;

Limeno, J ;

Guzman, C ;

Demetri, GD .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) :5484-5492

[6]

GlaxoSmithKline, 2010, VOTR PAZ TABL PRESCR

[7]

*GLAXOSMITHKLINE, 2011, INV BROCH PAZ GW7860

[8]

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? [J].

Gotink, Kristy J. ;

Verheul, Henk M. W. .

ANGIOGENESIS, 2010, 13 (01) :1-14

[9]

(Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor [J].

Hamberg, Paul ;

Verweij, Jaap ;

Sleijfer, Stefan .

ONCOLOGIST, 2010, 15 (06) :539-547

[10]

Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor [J].

Harris, Philip A. ;

Boloor, Amogh ;

Cheung, Mui ;

Kumar, Rakesh ;

Crosby, Renae M. ;

Davis-Ward, Ronda G. ;

Epperly, Andrea H. ;

Hinkle, Kevin W. ;

Hunter, Robert N., III ;

Johnson, Jennifer H. ;

Knick, Victoria B. ;

Laudeman, Christopher P. ;

Luttrell, Deirdre K. ;

Mook, Robert A. ;

Nolte, Robert T. ;

Rudolph, Sharon K. ;

Szewczyk, Jerzy R. ;

Truesdale, Anne T. ;

Veal, James M. ;

Wang, Liping ;

Stafford, Jeffrey A. .

JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (15) :4632-4640

← 1 2 3 4 →